Tortoise Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

Tortoise Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,200	Closed	-$6.6K	–	798
2023 Q1	$6.6K	Hold	1,200	–	–	﹤0.01%	590
2022 Q4	$5.51K	Hold	1,200	–	–	﹤0.01%	601
2022 Q3	$7K	Hold	1,200	–	–	﹤0.01%	580
2022 Q2	$5K	Hold	1,200	–	–	﹤0.01%	597
2022 Q1	$6K	Hold	1,200	–	–	﹤0.01%	557
2021 Q4	$10K	Hold	1,200	–	–	﹤0.01%	488
2021 Q3	$11K	Hold	1,200	–	–	﹤0.01%	463
2021 Q2	$15K	Hold	1,200	–	–	﹤0.01%	421
2021 Q1	$11K	Buy	+1,200	New	+$10.5K	﹤0.01%	437
2017 Q3	–	Sell	-109	Closed	-$7K	–	504
2017 Q2	$7K	Hold	109	–	–	﹤0.01%	387
2017 Q1	$9K	Hold	109	–	–	﹤0.01%	347
2016 Q4	$5K	Hold	109	–	–	﹤0.01%	403
2016 Q3	$8K	Hold	109	–	–	﹤0.01%	343
2016 Q2	$7K	Hold	109	–	–	﹤0.01%	363
2016 Q1	$25K	Sell	109 -53	-33%	-$12.8K	0.01%	239
2015 Q4	$52K	Buy	+162	New	+$44K	0.02%	208

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Tortoise Investment Management's ZVRA Position: Q2 2023 in Review

Tortoise Investment Management sold out of Zevra Therapeutics (ZVRA) in Q2 2023, closing a stake of 1,200 shares — an estimated $6.6K sold.

Tortoise Investment Management first reported a position in ZVRA in Q4 2015 and held it in 16 quarters. The position peaked at $52K in Q4 2015. 71 funds tracked by Wall St. Rank hold ZVRA as of Q2 2023.

Tortoise Investment Management reported no remaining Zevra Therapeutics position as of Q2 2023 after selling out during the quarter.
Tortoise Investment Management sold 1,200 Zevra Therapeutics shares in Q2 2023, an estimated $6.6K.
Tortoise Investment Management first reported a position in Zevra Therapeutics in Q4 2015 and held it in 16 quarters.
Tortoise Investment Management's Zevra Therapeutics position peaked at $52K in Q4 2015.
71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2023.

Based on Tortoise Investment Management's 13F filing for Q2 2023, filed 7 Aug 2023.